What is the most common and effective medication for treating constipation in otherwise healthy school‑aged children (approximately 5–12 years)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Polyethylene Glycol (PEG) is the Most Common and Effective First-Line Medication for Constipation in School-Aged Children

Polyethylene glycol (PEG) should be the standard first-line pharmacological treatment for functional constipation in school-aged children (5-12 years), with a typical starting dose of 0.4-0.8 g/kg/day (approximately 17g daily for an average-sized child), titrated based on response.

Why PEG is the Clear Choice

The most recent and highest-quality evidence strongly supports PEG as superior to other laxatives. A 2025 systematic review and meta-analysis of 59 randomized controlled trials involving 7,045 children demonstrated that PEG is probably more effective than placebo (RR 1.74,95% CI 1.25-2.41) and may be more effective than lactulose (RR 1.35,95% CI 1.11-1.64) 1. This represents the most comprehensive pediatric constipation evidence to date.

Key Advantages of PEG:

  • Superior efficacy: Produces 0.95 more stools per week compared to lactulose 1
  • Better tolerability: Children require fewer additional laxative therapies (18% vs 30% with lactulose) 2
  • Excellent safety profile: Well-tolerated with minimal serious adverse events 1, 3
  • Better acceptance: Children tolerate PEG better than alternative laxatives due to improved palatability 3

Practical Dosing Algorithm

Initial Treatment:

  • Start with PEG 0.4-0.8 g/kg/day (typically 17g daily mixed in 8 oz water)
  • Can be given once daily or divided into two doses
  • Titrate every 3-7 days based on stool frequency and consistency
  • Maximum dose: 1.5 g/kg/day

Goal: Achieve one non-forced bowel movement every 1-2 days with soft, comfortable stools

When PEG Alone is Insufficient

If constipation persists after optimizing PEG dosing:

  1. Rule out fecal impaction - May require disimpaction before maintenance therapy works
  2. Add a stimulant laxative if needed:
    • Bisacodyl 5-10 mg daily (for short-term use)
    • Senna 8.6-17.2 mg daily
  3. Consider magnesium oxide 400-500 mg daily as an alternative osmotic agent 4

Important Caveats

Common side effects to counsel families about:

  • Bloating and abdominal discomfort (usually transient)
  • Flatulence
  • Diarrhea (indicates dose is too high - reduce by 25-50%)

Critical pitfall to avoid: Do not rely on dietary fiber supplements (like psyllium) as primary therapy. These require adequate hydration and are unlikely to control functional constipation effectively in children 5. Fiber may be considered as an adjunct only with adequate fluid intake 6.

Alternative Agents Have Limited Roles

While newer agents like linaclotide showed promise in adults, pediatric data reveals it may not be more effective than placebo for treatment success (RR 1.21,95% CI 0.69-2.13), though it does increase defecation frequency 1. Prucalopride similarly showed no clear benefit over placebo in children (RR 1.68,95% CI 0.77-3.68) 1.

Lactulose remains a reasonable alternative if PEG is unavailable or not tolerated, but it is less effective and may cause more bloating 1, 2.

Non-Pharmacological Essentials

While medication is central, always address:

  • Behavioral toilet training: Scheduled sitting after meals
  • Adequate fluid intake: Essential for any laxative to work optimally
  • Physical activity: Encourage regular exercise when appropriate

The evidence clearly establishes PEG as both the most common and most effective medication for school-aged children with functional constipation, with a robust safety profile supporting its use as standard first-line therapy 1, 7.

Related Questions

What is the most appropriate medication for constipation in a healthy 15-year-old adolescent?
What is the recommended management of constipation associated with methylphenidate therapy in children and adolescents?
In a 2‑year‑old with severe ARFID who is receiving polyethylene glycol (PEG) for constipation and has developed new motor tics and worsening aggression, is there a medically reasonable basis for a supervised trial off PEG, what evidence supports or refutes an association, what alternative maintenance laxatives (including lactulose, magnesium hydroxide, and magnesium citrate) are appropriate, where does magnesium citrate fall outside guideline‑supported chronic use, what pediatric safety, dosing, and monitoring considerations apply, and what information do the pediatric gastroenterologist and developmental pediatrician need before agreeing to such a trial?
What is the recommended treatment regimen for constipation in a school‑age child, including dietary measures and first‑line pharmacologic therapy?
What is the appropriate management for a 9‑year‑old child with two weeks of constipation, no bowel movements, who has not responded to polyethylene glycol (PEG 3350, Miralax) despite adequate fiber and fluid intake?
What is the appropriate dosage of potassium chloride for a pregnant woman with hypokalemic periodic paralysis?
What is the appropriate daily number of potassium chloride tablets (8 mEq each) to administer, not exceeding 20 mEq per day?
What is the likely diagnosis and recommended evaluation for a child with chronic loose, mushy, mucus‑laden stools containing occasional bright‑red blood streaks?
What is the recommended treatment approach for an adult with active Crohn’s disease, including induction and maintenance therapy?
How should I manage a patient with severe hypotension (blood pressure 68/40 mm Hg) and markedly elevated serum glutamic‑pyruvic transaminase (SGPT/ALT)?
How should Sayana Press (medroxyprogesterone acetate 104 mg) be administered as a subcutaneous injection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.